Autopsy report · NCT04636814

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

“Strategic decision by Sponsor; not due to safety reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 4 years 5 months before it stopped.
• 3,973 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Chiesi Farmaceutici S.p.A.

Sponsor type

Industry

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

CHF6001 1600µg; CHF6001 3200µg; Placebo; Roflumilast

Participants

3,973

Sites

460

Countries

Argentina, Austria, Bosnia and Herzegovina, Bulgaria, Chile, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Israel and more

Trials that died the same way

• Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
  “Sponsor decision (not due to safety concerns)” (89% match in meaning)
• Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
  “Sponsor decision due to strategic considerations” (89% match in meaning)
• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
  “sponsor decision (not for safety)” (89% match in meaning)
• A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
  “Sponsor decision; Not a safety decision” (88% match in meaning)
• High-Risk Skin Cancers With Atezolizumab Plus NT-I7
  “Strategic decision by sponsor” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.